Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883636 | 0.75 | CA1 (0.36) | CA12CA1CA9APLNRPSMD10 | |
| SCHEMBL15284136 | 0.75 | CA12 (0.38) | CA12CA1CA9APLNRPSMD10 | |
| SCHEMBL27248448 | 0.75 | CA12 (0.38) | CA12CA1CA9APLNRPSMD10 | |
| SCHEMBL15284498 | 0.75 | CA12 (0.38) | CA12CA1CA9APLNRPSMD10 | |
| SCHEMBL30467054 | 0.75 | ESR1 (0.33) | — | |
| SCHEMBL30467049 | 0.75 | ESR1 (0.33) | — | |
| SCHEMBL20332538 | 0.75 | ESR1 (0.33) | — | |
| SCHEMBL932051 | 0.74 | HTR2A (0.44) | CA12CA1CA9PSMD10ALDH1A1 | |
| SCHEMBL30292889 | 0.73 | HRH3 (0.44) | CA12CA1CA9PSMD10MEN1 | |
| SCHEMBL4316004 | 0.73 | HRH3 (0.44) | CA12CA1CA9PSMD10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | MINORYX THERAPEUTICS S.L. (ES) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731963-B2 | Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]-methyl]-2,4-thiazolidinedione and salts thereof | CYP3A5, CYP3A4, UGT1A4 | CA12 4505/4885CA1 4691/4885CA9 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.